Trial Profile
ML21206 - Bevacizumab in Chronic Lymphocytic Leukemia: A Proof of Concept Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors Roche
- 15 Nov 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 15 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.